Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) has announced plans to release new clinical data from its Phase 1/2 ACHIEVE clinical trial on January 10, 2025. The company will host a webcast and investor conference call at 8:00 a.m. ET on the same day, with a press release to be issued before the event. The presentation will be accessible through the Events & Presentations page on Dyne's website, with a replay available for 90 days afterward. An accompanying slide presentation will also be provided for investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DYN declined 31.15%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Investor Conference Call and Webcast
The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
About Dyne Therapeutics
Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mike Hencke
Kendall Investor Relations
ir@dyne-tx.com
Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938
FAQ
When will Dyne Therapeutics (DYN) release new ACHIEVE trial data?
How can investors access Dyne Therapeutics' (DYN) ACHIEVE trial data presentation?
How long will the replay of DYN's ACHIEVE trial data presentation be available?
What phase is Dyne Therapeutics' ACHIEVE trial currently in?
